Rp-8-CPT-cAMPS

Rp-8-CPT-cAMPS

• CAS Number: 129735-01-9
• UNSPSC Description: Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI[1][2].
• Target Antigen: PKA
• Type: Reference compound
• Related Pathways: Stem Cell/Wnt;TGF-beta/Smad
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/rp-8-cpt-camps.html
• Solubility: 10 mM in DMSO
• Smiles: O[C@H]1[C@](O[C@@](CO2)([H])[C@@]1([H])O[P@@]2(S)=O)([H])N3C4=NC=NC(N)=C4N=C3SC(C=C5)=CC=C5Cl
• Molecular Weight: 487.88
• References & Citations: [1]Dostmann WR , et, al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem. 1990 Jun 25;265(18):10484-91.|[2]Roscioni SS, et, al. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res. 2009 Sep 29;10(1):88.|[3]Chaisakul J, et, al. In vivo and in vitro cardiovascular effects of Papuan taipan (Oxyuranus scutellatus) venom: Exploring "sudden collapse". Toxicol Lett. 2012 Sep 3;213(2):243-8.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported